CoronaryAtlas logo
CoronaryAtlas
lactosylceramide
Pathway / Plaque inflammation

lactosylceramide

lipid

Lactosylceramide regulates monocyte recruitment and inflammatory signaling, bridging lipid retention and plaque inflammation.

Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleSphingolipid mediator of plaque inflammation, monocyte migration, and atherothrombotic initiation.
Also acts inLipid entry/oxidation, Platelet activation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
26
C — non-Type-I
48
A — assay feasibility
40
E — evidence strength
17
T1DI (composite)
3
Specificity differential (R−C)-21.7
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only

Literature evidence(3)